On 10 September, FillMed hosted a press panel to introduce Juvelook and Lenisna, a new generation of hybrid biostimulator injectables – and the world’s first and only reversible hybrid biostimulators. The panel, hosted by Dr Christine Hall, featured panellists Dr Lisa Dinley, Poppy Pilram, and Mo Harb, who shared insights into the innovation, safety, and patient benefits of these treatments.
Q: For people who haven’t heard of Juvelook or Lenisna before, how would you describe them in simple terms?
A: They are next-generation hybrid biostimulators, designed to treat the full face — including delicate areas that traditional biostimulators cannot safely address.
Q: How are these treatments different from fillers or other injectables, such as Sculptra?
A: They are completely different. Juvelook and Lenisna introduce new treatment possibilities with unique safety features, most notably reversibility. This sets them apart from older biostimulators.
Q: With K-beauty dominating the skincare space, and Juvelook holding around 90% market share in Korea, how do you see this impacting the UK aesthetics market?
A: We see it having a very positive impact. For practitioners, Juvelook’s strong safety profile, ease of use, and broad indications will reduce barriers to adopting biostimulators in clinic. For patients, the fact that Juvelook is already so widely trusted in Korea provides peace of mind. Its unique USPs — including being the world’s first and only reversible hybrid biostimulators, treating delicate areas that others cannot, and delivering both instant and long-lasting natural results — offer reassurance that this is a proven innovation designed with patient safety and satisfaction at its core.
Q: What makes Juvelook particularly appealing compared to mainstream fillers in Korea?
A: Juvelook’s appeal lies in its dual-action formula: hyaluronic acid (HA) provides immediate hydration and skin radiance, while PDLLA stimulates collagen production for gradual, long-term improvement. Unlike traditional fillers that simply add volume, Juvelook works with the body’s own natural regenerative processes, leading to fresher, healthier-looking skin that feels both natural and lasting.
Safety & Trust
Q: Safety is a big concern with injectables. What makes Juvelook and Lenisna safer than older options?
A: These products have been on the market since 2014 and are widely and safely used across Korea and Europe. Their unique manufacturing process ensures a consistent safety record.
Q: Are nodules or visual disturbances a concern with these treatments?
A: No nodules have been reported with Juvelook or Lenisna, thanks to their unique formulation and manufacturing process — including particle size and their combination with HA.
Q: You mentioned reversibility — why does this matter?
A: Traditional biostimulators cannot be reversed, which can deter both practitioners and patients. Juvelook and Lenisna are the first and only reversible hybrid biostimulators, offering an important safety net in the rare event of a complication.
Q: With counterfeit injectables and unqualified providers in the news, how can consumers be sure they’re getting authentic products?
A: The patients should be asking information on their practitioner, whether that be qualifications, experience and relevant product queries relating to their chosen treatment. The practitioner should be able to answers questions on the products they are using. Patients can also check with the manufacturers as to who is legally allowed to sell their product, sadly counterfeit products are becoming more frequent so both patients and practitioners should be more stringent.
Results
Q: What kind of results can patients expect, and how quickly?
A: Results are dual-phase: instant hydration from the HA, followed by longer-term biostimulation as new collagen develops.
Q: Who is the ideal candidate for Juvelook versus Lenisna?
A: After a thorough consultation, patients that are more concerned about overall skin laxity and volume loss may be better suited for Lenisna, whereas someone more concerned about their under eyes or skin quality may be better suited for Juvelook. However, both products can be used in a layering technique should a patient have the suitable indications.
Q: Will patients look “done” or over-treated?
A: No — results are very natural. Because the treatments stimulate the body’s own collagen and elastin, outcomes are subtle, fresh, and regenerative, in line with Korean and French beauty philosophies.
Practical Questions
Q: What’s the treatment process like?
A: A session takes about 30 minutes for a full face. Downtime is minimal — patients may experience mild swelling, usually resolving within 24 hours.
Q: How many sessions are needed?
A: We recommend a course of three treatments for full effect.
Q: Can these treatments be combined with fillers or skin boosters?
A: Yes. Juvelook and Lenisna work well alongside other treatments — think of them as the foundation of the “house,” supporting and enhancing results from other aesthetic treatments.
Consumer Confidence
Q: With so many treatments launching, why should consumers trust Juvelook and Lenisna?
A: We don’t compare directly to other brands, but Juvelook and Lenisna offer genuinely new technology, with proven safety and reversibility — something the aesthetics market has been waiting for.
Q: Are these treatments better for prevention (30s–40s) or correction (visible ageing)?
A: Both. Biostimulation supports preventative treatment in younger patients and regenerative treatment in older patients.
Q: What’s the key message you’d like patients to remember?
A: Treatments like Juvelook and Lenisna are an investment in your skin — much like skincare, but working from the inside out.
